EQUILLIUM INC

Equillium showcases its preclinical EQ504 data at the 7th International AHR Conference, aiming to boost collaboration and accelerate autoimmune therapy development.

Equillium Inc. earns a “Strong Buy” from Raymond James, boosting investor confidence as its autoimmune pipeline shows promise and may lift stock prices.

Equillium Inc. is navigating a tumultuous period amidst corporate governance changes, financial instability, and a need for transparent communication with investors.

Equillium Inc. faces financial challenges and market volatility, but its commitment to addressing autoimmune and inflammatory disorders remains a compelling narrative.